Moderna and Carisma Therapeutics partner to develop CAR-M therapeutics
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Biogen paid Ionis a US $ 60 million one-time upfront payment
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities
Subscribe To Our Newsletter & Stay Updated